What's Happening?
The FDA has approved Ascendis Pharma's navepegritide, marketed as Yuviwel, for boosting growth in children aged 2 years and older with achondroplasia. Yuviwel is the first drug to use weekly dosing to provide sustained exposure to C-type natriuretic peptide
(CNP), addressing a key pathway affected in achondroplasia. The approval follows pivotal findings from the Phase 2b APPROACH study, which showed significant growth velocity improvement in patients. Yuviwel's approval includes a rare pediatric disease priority review voucher, allowing Ascendis to expedite future drug reviews.
Why It's Important?
Yuviwel's approval marks a significant advancement in the treatment of achondroplasia, offering a more convenient weekly dosing schedule compared to daily injections. This could improve patient compliance and outcomes, transforming the management of achondroplasia. The approval also highlights the potential for innovative therapies to address rare diseases, providing new options for patients and families affected by achondroplasia.
What's Next?
Yuviwel will be available to patients in the early part of the second quarter, with prescribing physicians overseeing its distribution. Ascendis plans to leverage its priority review voucher for future drug approvals, potentially accelerating the development of new therapies. The company faces competition from other achondroplasia treatments, including BioMarin's Voxzogo and BridgeBio's infigratinib, which is in late-stage development.
